RecruitingNCT07010484

Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica

Sponsor

Kresten Krarup Keller

Enrollment

149 participants

Start Date

Aug 21, 2025

Study Type

OBSERVATIONAL

Conditions

Polymyalgia Rheumatica (PMR)

Summary

Polymyalgia rheumatica (PMR) is the most common chronic inflammatory rheumatic disease among the elderly and is characterized by proximal extremity pain and fatigue. Treatment with prednisolone carries several significant adverse effects, and it is therefore essential to avoid unnecessary treatment. However, clinical diagnosis and even imaging such as positron emission tomography and computed tomography (PET/CT) has low diagnostic accuracy, which decrease after start of prednisolone. The purpose is to evaluate a new method to diagnose PMR with PET/CT using magnetic resonance imaging (MRI) for informing the interpretation of PET in 111 patients suspected of PMR at baseline and after 8 weeks prednisolone treatment. In addition, a treatment initiation strategy guided by clinical diagnosis combined with PET will be evaluated in 100 patients with newly diagnosed PMR.

Eligibility

Min Age: 50 Years

Inclusion Criteria3

Patients suspected of PMR seen at the Department of Rheumatology/internal medicine in Aarhus, Silkeborg, Horsens, Gødstrup, Randers, and Svendborg.
Age above 50.
Proximal extremity pain.

Exclusion Criteria9

Oral, intravenous, intra-articular or intramuscular glucocorticoids within the last 2 months.
Previous prednisolone treatment for GCA/PMR.
Unable to give consent.
Proximal extremity pain duration for more than one year.
Symptoms of GCA (headache, scalp tenderness, jaw or tongue claudication, vision disturbances attributable to GCA, limb claudication).
Active malignant cancers within the last 5 years (except basal cell carcinoma).
Other known inflammatory rheumatic diseases (e.g. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritis, gout).
Uncontrolled diseases (e.g. severe active asthma, cardiac disease with NYHA class IV)
For MRI: Implants contraindicating MRI and BMI\>150 kg.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.